COLUMBUS, Ohio – The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) is offering free prostate cancer screenings from 8 a.m. to 4 p.m. on Friday (9/30), in the hospital’s first floor clinic at 300 West 10th Ave.
More than 500 men are expected to be screened by receiving a digital rectal exam and a prostate-specific antigen blood test. Also on display will be the da Vinci surgical system that the skilled surgeons at The James use to assist with minimally invasive robotic prostate cancer surgery at Ohio State’s Center for Advanced Robotic Surgery.
Registration is recommended for the screening, and appointments can be scheduled by calling The JamesLine at 1-800-293-5066. Walk-in appointments are also available. Complimentary garage parking is provided.
Prostate cancer is the most common cancer in men, but it is also one of the most curable if detected early. The American Cancer Society estimates that more than 240,000 men in the United States will develop prostate cancer and more than 33,000 will die from it this year. Yearly exams are recommended for many men as one way of detecting the disease at a stage when it can be treated successfully.
Based on their abnormal screening test results, 114 of the 482 men who were screened during last year’s event – almost 24 percent – were encouraged to seek further testing.
Annual screenings are recommended for those: age 50 or older; age 45 or older and African-American; or age 40 or older with a family history of prostate cancer.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 210-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by U.S. News & World Report.
# # #
Contact: Eileen Scahill, Medical Center Public Affairs and Media Relations, 614-293-3737, or Eileen.Scahill@osumc.edu